UPM, MVP meterai perjanjian untuk komersial vaksin baharu sampar ayam
SERDANG, 30 Dis: Universiti Putra Malaysia (UPM) dan syarikat Malaysian Vaccines and Pharmaceuticals Sdn Bhd (MVP) memeterai perjanjian pelesenan (licensing agreement) untuk MVP mengkomersialkan inovasi vaksin generasi baharu bagi mengawal penyakit sampar ayam (Newcastle Disease) yang menyerang ayam...
| Main Author: | |
|---|---|
| Format: | UPM News |
| Language: | English English |
| Published: |
Pejabat Strategi Korporat dan Komunikasi, Universiti Putra Malaysia
2019
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/76773/1/UPM%2C%20MVP%20meterai%20perjanjian%20untuk%20komersial%20vaksin%20baharu%20sampar%20ayam.pdf http://psasir.upm.edu.my/id/eprint/76773/2/UPM%2C%20MVP%20Meterai%20Perjanjian%20Untuk%20Komersial%20Vaksin%20Baharu%20Sampar%20Ayam%20_%20Universiti%20Putra%20Malaysia.pdf |
Internet
http://psasir.upm.edu.my/id/eprint/76773/1/UPM%2C%20MVP%20meterai%20perjanjian%20untuk%20komersial%20vaksin%20baharu%20sampar%20ayam.pdfhttp://psasir.upm.edu.my/id/eprint/76773/2/UPM%2C%20MVP%20Meterai%20Perjanjian%20Untuk%20Komersial%20Vaksin%20Baharu%20Sampar%20Ayam%20_%20Universiti%20Putra%20Malaysia.pdf